JP2021169449A - マイクロrna組成物並びにその作製及び使用方法 - Google Patents
マイクロrna組成物並びにその作製及び使用方法 Download PDFInfo
- Publication number
- JP2021169449A JP2021169449A JP2021092044A JP2021092044A JP2021169449A JP 2021169449 A JP2021169449 A JP 2021169449A JP 2021092044 A JP2021092044 A JP 2021092044A JP 2021092044 A JP2021092044 A JP 2021092044A JP 2021169449 A JP2021169449 A JP 2021169449A
- Authority
- JP
- Japan
- Prior art keywords
- seq
- mir
- cells
- cell
- stem cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
- A61K9/1273—Polymersomes; Liposomes with polymerisable or polymerised bilayer-forming substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Dispersion Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
- Developmental Biology & Embryology (AREA)
- Transplantation (AREA)
- Cell Biology (AREA)
Abstract
Description
以下の実施例は、本開示を例示するために提供される。これらの実施例は、本開示の範囲を限定するとして意図されず、そのように解釈されるべきではない。
Claims (11)
- 加齢性障害の治療において用いる、前記単離されたマイクロRNAは、miR−4497(配列番号6);miR−1303(配列番号7);miR−619−5p(配列番号8);及びその機能的バリアント;から選択される1、2、又は3の配列と少なくとも80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%又は99%の配列同一性がある、1、2、又は3の単離されたマイクロRNAを含む組成物であって、前記加齢性障害の治療は、CD34+細胞のクローン形成能の増加を含む、組成物。
- 前記組成物は、さらにベヒクルを含む、請求項1に記載の組成物。
- 前記ベヒクルは、ナノ粒子、ミセル、リポソーム、ニオソーム、微粒子、シクロデキストリン又はその組み合わせを含む、請求項2に記載の組成物。
- 修復幹細胞の組成物を調製する方法であって:
(i)修復幹細胞を生成するために、請求項1〜3に記載の組成物に含まれるmiR−4497(配列番号6);miR−1303(配列番号7);miR−619−5p(配列番号8);及びその機能的バリアント;から選択される1、2、又は3の配列と少なくとも80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%又は99%の配列同一性がある、1、2、又は3の単離されたマイクロRNAの発現に対する核酸配列を有する少なくとも1つのベクター構築物を成体幹細胞の試料に導入するステップ;及び、
(ii)前記修復幹細胞を回収するステップ;
を含む方法。 - 前記少なくとも1つのベクターは、前記2又は3のマイクロRNAの各々に作動可能に連結されるプロモーター配列を含む、請求項4に記載の方法。
- 前記修復幹細胞は、前記2又は3のマイクロRNAを構成的に発現する、請求項5に記載の方法。
- 前記修復幹細胞は、前記2又は3のマイクロRNAを誘導的に発現する、請求項5に記載の方法。
- 成体幹細胞を含む医薬製剤であって、前記成体幹細胞は、(i)請求項1〜3に記載の組成物に含まれるmiR−4497(配列番号6);miR−1303(配列番号7);miR−619−5p(配列番号8);及びその機能的バリアント;から選択される1、2、又は3の配列と少なくとも80%、85%、90%、91%、92%、93%、94%、95%、96%、97%、98%又は99%の配列同一性がある、1、2、又は3の単離されたマイクロRNAの発現に対するオリゴヌクレオチドに作動可能に連結されるプロモーター要素を有する少なくとも1つのプラスミド、並びに、(ii)増殖因子、サイトカイン、ホルモン、及びその組み合わせを含む群から選択される少なくとも1つの活性物質を含む、医薬製剤。
- 請求項1〜3のいずれか一項に記載の組成物を含む医薬製剤であって、前記組成物は、miR−4497(配列番号6);miR−1303(配列番号7);及びmiR−619−5p(配列番号8);を含む医薬製剤。
- さらに、キャリア、賦形剤、安定剤、抗酸化剤、ポリペプチド、タンパク質、親水性ポリマー、アミノ酸、炭水化物、キレート剤、糖アルコール塩形成対イオン、非イオン性界面活性剤、又は、その組み合わせを含む、請求項9に記載の製剤。
- 請求項8に記載の製剤を含むキット。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662329486P | 2016-04-29 | 2016-04-29 | |
US62/329,486 | 2016-04-29 | ||
US201762482465P | 2017-04-06 | 2017-04-06 | |
US62/482,465 | 2017-04-06 | ||
JP2018556440A JP6999575B2 (ja) | 2016-04-29 | 2017-04-28 | マイクロrna組成物並びにその作製及び使用方法 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556440A Division JP6999575B2 (ja) | 2016-04-29 | 2017-04-28 | マイクロrna組成物並びにその作製及び使用方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021169449A true JP2021169449A (ja) | 2021-10-28 |
JP7343549B2 JP7343549B2 (ja) | 2023-09-12 |
Family
ID=60158119
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556440A Active JP6999575B2 (ja) | 2016-04-29 | 2017-04-28 | マイクロrna組成物並びにその作製及び使用方法 |
JP2021092044A Active JP7343549B2 (ja) | 2016-04-29 | 2021-06-01 | マイクロrna組成物並びにその作製及び使用方法 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018556440A Active JP6999575B2 (ja) | 2016-04-29 | 2017-04-28 | マイクロrna組成物並びにその作製及び使用方法 |
Country Status (9)
Country | Link |
---|---|
US (1) | US11203754B2 (ja) |
EP (1) | EP3436081A4 (ja) |
JP (2) | JP6999575B2 (ja) |
KR (1) | KR20180130589A (ja) |
CN (1) | CN109475645A (ja) |
BR (1) | BR112018072198A2 (ja) |
CA (1) | CA3023468A1 (ja) |
TW (1) | TW201739458A (ja) |
WO (1) | WO2017190000A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
JP6353073B2 (ja) | 2013-12-20 | 2018-07-04 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | 細胞回復のための組成物並びにその作製及び使用方法 |
JP6999575B2 (ja) | 2016-04-29 | 2022-01-18 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
US10717981B2 (en) | 2018-01-18 | 2020-07-21 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
WO2020190888A1 (en) * | 2019-03-18 | 2020-09-24 | Advanced ReGen Medical Technologies, LLC | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
KR20210099917A (ko) | 2020-02-05 | 2021-08-13 | 이윤하 | 범죄자 유무 알리미 |
CN114107209B (zh) * | 2021-11-25 | 2024-02-02 | 青岛市市立医院 | 一种非治疗目的的高表达miR-146a-5p的外泌体抑制THP-1分化和巨噬细胞M1极化的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015182781A1 (ja) * | 2014-05-30 | 2015-12-03 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
WO2015190542A1 (ja) * | 2014-06-11 | 2015-12-17 | 東レ株式会社 | 胆道がんの検出キット又はデバイス及び検出方法 |
Family Cites Families (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2984164A (en) | 1955-01-12 | 1961-05-16 | Voigtlaender Ag | Automatic exposure adjustment in photographic cameras |
US3122333A (en) | 1961-02-23 | 1964-02-25 | Gen Mills Inc | Tape quantity sensing and winding control apparatus |
US3083939A (en) | 1961-03-02 | 1963-04-02 | Jr Edward J Gallagher | Floating shockproof and vibrationless assembly for delicate instrument panel mount |
US3436081A (en) | 1967-06-26 | 1969-04-01 | Sandor A Ungar | Game equipment |
US6319471B1 (en) | 1992-07-10 | 2001-11-20 | Gambro, Inc. | Apparatus for producing blood component products |
US20040199935A1 (en) | 1999-06-30 | 2004-10-07 | Chapman Karen B. | Cytoplasmic transfer to de-differentiate recipient cells |
EP1231956A2 (en) | 2000-03-09 | 2002-08-21 | Gambro, Inc. | Extracorporeal blood processing method and apparatus |
AU2002952944A0 (en) | 2002-11-27 | 2002-12-12 | Human Genetic Signatures Pty Ltd | Restoration of methylation states in cells |
US20080213812A1 (en) | 2003-09-29 | 2008-09-04 | Andrews William H | Methods and compositions for modulating telomerase reverse transcriptase (TERT) expression |
US20050158285A1 (en) | 2003-12-09 | 2005-07-21 | Giampapa Vincent C. | Method of re-profiling adult stem cells using embryonic stem cell electromagnetic signals |
US20080268429A1 (en) | 2004-06-02 | 2008-10-30 | Sourcepharm, Inc. | Rna - Containing Microvesicles and Methods Therefor |
AU2005262319A1 (en) | 2004-07-01 | 2006-01-19 | Orthogen Ag | Immunosuppressive exosomes |
US20070196918A1 (en) | 2004-07-15 | 2007-08-23 | Sayre Chauncey B | Reprogramming of adult human testicular stem cells to pluripotent germ-line stem cells |
EP1809740B1 (en) | 2004-11-08 | 2018-08-29 | The Johns Hopkins University | Cardiac stem cells |
EP2400020A1 (en) * | 2005-04-29 | 2011-12-28 | The Rockfeller University | Human micrornas and methods for inhibiting same |
WO2007016245A2 (en) | 2005-07-29 | 2007-02-08 | Vivicells International, Llc | Reprogramming of adult or neonic stem cells and methods of use |
BRPI0617664B8 (pt) | 2005-10-21 | 2021-05-25 | Chugai Pharmaceutical Co Ltd | uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio |
US20090011004A1 (en) | 2005-12-30 | 2009-01-08 | Philadelphia Health & Education Corp., D/B/A/ Drexel University Of College Of Medicine | Improved carriers for delivery of nucleic acid agents to cells and tissues |
EP1810686A1 (en) | 2006-01-19 | 2007-07-25 | Academisch Ziekenhuis Leiden | Means and methods for modulating stem cell mobilization |
GB0605450D0 (en) | 2006-03-17 | 2006-04-26 | Intercytex Ltd | Cell co-culture |
KR100832592B1 (ko) | 2006-08-17 | 2008-05-27 | 박현숙 | 폴리머 막을 이용한 줄기세포와 피더세포의 공배양방법 |
CA2669304C (en) | 2006-11-30 | 2016-10-25 | Medipost Co., Ltd. | Use of a composition contaning human umbilical cord blood-derived mesenchymal stem cell for inducing differentiation and proliferation of neural precursor cells or neural stem cells to neural cells |
KR100959995B1 (ko) | 2006-12-01 | 2010-05-28 | 메디포스트(주) | 인간 제대혈 유래 간엽 줄기세포를 유효성분으로 포함하는,신경전구세포 또는 신경줄기세포의 신경세포로의 분화 및증식 유도용 조성물 |
US8586725B2 (en) | 2007-02-16 | 2013-11-19 | The Johns Hopkins University | MicroRNAome |
US9205112B2 (en) | 2007-04-23 | 2015-12-08 | Creative Medical Health, Inc. | Combination treatment of cardiovascular disease |
US8491885B2 (en) | 2007-07-16 | 2013-07-23 | Catholic University Industry Academic Cooperation Foundation | Method for promoting the self-renewal of adult stem cells using mesenchymal stromal cells |
US9090894B2 (en) | 2007-12-17 | 2015-07-28 | California Institute Of Technology | Modulating immune system development and function through microRNA MIR-146 |
WO2009086425A1 (en) | 2007-12-28 | 2009-07-09 | Fate Therapeutics, Inc. | Methods for reprogramming cells to a pluripotent state and therapeutic applications related thereto |
KR101640381B1 (ko) | 2008-02-22 | 2016-07-18 | 에이전시 포 사이언스, 테크놀로지 앤드 리서치 | 중간엽 줄기세포 입자 |
EP2294196A1 (en) | 2008-06-06 | 2011-03-16 | Centre National de la Recherche Scientifique - CNRS | Use of endo-lysosomal system and secreted vesicles (exosome-like) in treatments and diagnostics based on small rna and experimental study of small rna |
EP2303292A4 (en) * | 2008-06-09 | 2013-01-02 | New York Medical College | COMPOSITIONS WITH CARDIAL STEM CELLS WITH OVEREXPRESSION OF SPECIFIC MICRORNAS AND METHOD FOR THEIR USE IN THE REPAIR OF THE CARED MYOCARDIC |
CN102802519B (zh) | 2009-06-25 | 2014-12-31 | 株式会社日立医疗器械 | 医用图像摄影装置 |
US20120258093A1 (en) | 2009-08-20 | 2012-10-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy |
CN102573856B (zh) | 2009-09-10 | 2016-10-26 | 弗莱明·韦林 | 用于制备微小rna 的方法及其治疗性应用 |
US20120253102A1 (en) | 2009-10-27 | 2012-10-04 | Cedars-Sinai Medical Center | External magnetic force for targeted cell delivery with enhanced cell retention |
EP2363136A1 (en) | 2010-03-02 | 2011-09-07 | Fresenius Medical Care Deutschland GmbH | Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease |
US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
US8980279B2 (en) | 2010-07-26 | 2015-03-17 | Qu Biologics | Personalized site-specific immunomodulation |
EP2603592A2 (en) | 2010-08-13 | 2013-06-19 | The University Court of the University of Glasgow | Therapeutic uses of microvesicles and related micrornas |
WO2012053976A1 (en) | 2010-10-18 | 2012-04-26 | Agency For Science, Technology And Research | Use of exosomes to promote or enhance hair growth |
US20120093885A1 (en) | 2010-10-18 | 2012-04-19 | Northwestern University | Therapeutic vesicles |
SG190450A1 (en) | 2010-12-20 | 2013-06-28 | Agency Science Tech & Res | Method of purifying exosomes |
SG183579A1 (en) | 2011-02-11 | 2012-09-27 | Agency Science Tech & Res | Methods of detecting therapeutic exosomes |
WO2012149557A1 (en) | 2011-04-28 | 2012-11-01 | New York University | miR-33 INHIBITORS AND USES THEREOF TO DECREASE INFLAMMATION |
US20140088006A1 (en) | 2011-05-18 | 2014-03-27 | Wellstat Therapeutics Corporation | Stem Cell Mobilization and Tissue Repair and Regeneration |
WO2012162741A1 (en) | 2011-06-01 | 2012-12-06 | Monash University | Enrichment of cardiomyocytes |
EP2535412A1 (en) | 2011-06-17 | 2012-12-19 | Universitat Pompeu-Fabra | New treatment for muscular dystrophies |
US8747915B1 (en) | 2011-09-14 | 2014-06-10 | Vincent C. Giampapa | Dietary supplement system for multifunctional anti-aging management and method of use |
WO2013048734A1 (en) | 2011-09-28 | 2013-04-04 | Tufts Medical Center, Inc. | Treatment and prevention of cardiovascular disease with cell derived lipid vesicles, microvesicles and exosomes |
WO2013066368A1 (en) | 2011-10-03 | 2013-05-10 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Use of mirna 126 to produce hematopoietic stem cells |
US9315776B2 (en) | 2011-11-09 | 2016-04-19 | National University Of Singapore | Wharton's jelly mesenchymal stem cells and uses thereof |
US9427450B2 (en) | 2012-01-31 | 2016-08-30 | Xon Cells, Inc. | Therapeutic immune modulation by stem cell secreted exosomes |
US20130236428A1 (en) | 2012-03-08 | 2013-09-12 | Vincent C. Giampapa | Reprogramming of Aged Adult Stem Cells |
US20150023935A1 (en) | 2012-03-08 | 2015-01-22 | Advanced ReGen Medical Technologies, Inc. | Reprogramming of Aged Adult Stem Cells |
US11286463B2 (en) | 2012-03-08 | 2022-03-29 | Advanced ReGen Medical Technologies, LLC | Reprogramming of aged adult stem cells |
GB201302468D0 (en) | 2013-02-12 | 2013-03-27 | Reneuron Ltd | Stem cell product |
WO2013170170A2 (en) | 2012-05-10 | 2013-11-14 | Board Of Regents Of The University Of Nebraska | Compositions and methods for gene therapy |
US9295696B2 (en) | 2012-06-08 | 2016-03-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | Compositions and methods for restoring or rejuvenating stem/progenitor cell function |
EP2687219A1 (en) | 2012-07-18 | 2014-01-22 | Universität Duisburg-Essen | Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions |
EP2877187B1 (en) | 2012-07-19 | 2019-06-12 | Reneuron Limited | Stem cell microparticles |
EP3563859B1 (en) * | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
CA2882966A1 (en) * | 2012-08-31 | 2014-03-06 | Aptamir Therapeutics, Inc. | Mirna modulators of chronic visceral inflammation |
US9492484B2 (en) | 2012-09-27 | 2016-11-15 | The Regents Of The University Of California | Cardiosphere derived cell population and methods of use |
CZ2012678A3 (cs) | 2012-10-04 | 2014-04-16 | Primecell A.S. | Způsob zpracování odběrů pupečníkové krve, zpracování a uchování získané odpadní pupečníkové krve a její terapeutické využití |
US9242000B2 (en) * | 2012-10-18 | 2016-01-26 | The Regents Of The University Of California | Micro-RNAs and micro-RNA inhibitors to modulate blood vessel growth, patterning, tumor growth and malignant disease and method for making and using them |
WO2014066545A1 (en) | 2012-10-26 | 2014-05-01 | Cedars-Sinai Medical Center | Therapeutic cells depleted of specific subpopulations of cells for use in tissue repair of regeneration |
EP2962709B1 (en) | 2013-02-26 | 2017-12-06 | Terumo Kabushiki Kaisha | Blood component separation apparatus |
EP2984164B1 (en) | 2013-04-09 | 2020-02-05 | Advanced Regen Medical Technologies, LLC | Compositions for cellular restoration and methods of making and using same |
WO2015022545A2 (en) * | 2013-08-14 | 2015-02-19 | Reneuron Limited | Stem cell microparticles and mirna |
GB201317889D0 (en) * | 2013-10-09 | 2013-11-20 | Reneuron Ltd | Product and use |
WO2015073625A2 (en) * | 2013-11-15 | 2015-05-21 | The Mclean Hospital Corporation | Synergistic genome-nonintegrating reprogramming by micrornas and transcription factors |
DK3076949T3 (da) | 2013-12-04 | 2019-11-25 | Univ Texas | Fremgangsmåde til isolering af kræftcelle-afledte eksosomer |
US10772911B2 (en) | 2013-12-20 | 2020-09-15 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
JP6353073B2 (ja) | 2013-12-20 | 2018-07-04 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | 細胞回復のための組成物並びにその作製及び使用方法 |
WO2015148534A1 (en) | 2014-03-24 | 2015-10-01 | Advanced ReGen Medical Technologies, LLC | Cell free compositions for cellular restoration and methods of making and using same |
US20160346334A1 (en) | 2014-02-05 | 2016-12-01 | Stc.Unm | Exosomes as a therapeutic for cancer |
US20150328263A1 (en) | 2014-05-14 | 2015-11-19 | University Of Maryland, Baltimore | Cardiac stem cells for cardiac repair |
KR20230113854A (ko) * | 2014-06-13 | 2023-08-01 | 도레이 카부시키가이샤 | 유방암 검출 키트 또는 디바이스 및 검출 방법 |
JP6878274B2 (ja) | 2014-10-03 | 2021-05-26 | シーダーズ−サイナイ・メディカル・センターCedars−Sinai Medical Center | 筋ジストロフィーの処置における心筋球由来細胞およびこのような細胞によって分泌されたエキソソーム |
WO2016057560A1 (en) | 2014-10-06 | 2016-04-14 | Cedars-Sinai Medical Center | Polarization of macrophages to a healing phenotype by cardiosphere-derived cells and by the exosomes secreted by such cells |
US10624849B2 (en) | 2015-09-28 | 2020-04-21 | Northwestern University | Targeted extracellular vesicles comprising membrane proteins with engineered glycosylation sites |
WO2017100587A1 (en) | 2015-12-09 | 2017-06-15 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting programmed cell death 1 ligand 1 (pd-l1) and methods of use thereof |
WO2017123662A1 (en) | 2016-01-11 | 2017-07-20 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
JP6999575B2 (ja) | 2016-04-29 | 2022-01-18 | アドヴァンスド リジェン メディカル テクノロジーズ,エルエルシー | マイクロrna組成物並びにその作製及び使用方法 |
JP2020529477A (ja) | 2017-08-04 | 2020-10-08 | シーダーズ—シナイ メディカル センター | がんの治療及び防止のためのカルディオスフィア由来細胞及びその細胞外小胞 |
US10717981B2 (en) | 2018-01-18 | 2020-07-21 | Advanced ReGen Medical Technologies, LLC | Therapeutic compositions and methods of making and using the same |
WO2020190888A1 (en) | 2019-03-18 | 2020-09-24 | Advanced ReGen Medical Technologies, LLC | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment |
-
2017
- 2017-04-28 JP JP2018556440A patent/JP6999575B2/ja active Active
- 2017-04-28 EP EP17790538.7A patent/EP3436081A4/en active Pending
- 2017-04-28 BR BR112018072198-0A patent/BR112018072198A2/pt not_active IP Right Cessation
- 2017-04-28 WO PCT/US2017/030117 patent/WO2017190000A1/en active Application Filing
- 2017-04-28 CA CA3023468A patent/CA3023468A1/en not_active Abandoned
- 2017-04-28 CN CN201780026347.5A patent/CN109475645A/zh active Pending
- 2017-04-28 KR KR1020187034249A patent/KR20180130589A/ko not_active Application Discontinuation
- 2017-04-28 US US15/581,705 patent/US11203754B2/en active Active
- 2017-04-28 TW TW106114364A patent/TW201739458A/zh unknown
-
2021
- 2021-06-01 JP JP2021092044A patent/JP7343549B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015182781A1 (ja) * | 2014-05-30 | 2015-12-03 | 東レ株式会社 | 膵臓がんの検出キット又はデバイス及び検出方法 |
WO2015190542A1 (ja) * | 2014-06-11 | 2015-12-17 | 東レ株式会社 | 胆道がんの検出キット又はデバイス及び検出方法 |
Also Published As
Publication number | Publication date |
---|---|
CN109475645A (zh) | 2019-03-15 |
EP3436081A4 (en) | 2019-07-24 |
US11203754B2 (en) | 2021-12-21 |
WO2017190000A1 (en) | 2017-11-02 |
US20170314019A1 (en) | 2017-11-02 |
EP3436081A1 (en) | 2019-02-06 |
TW201739458A (zh) | 2017-11-16 |
CA3023468A1 (en) | 2017-11-02 |
JP6999575B2 (ja) | 2022-01-18 |
KR20180130589A (ko) | 2018-12-07 |
JP7343549B2 (ja) | 2023-09-12 |
BR112018072198A2 (pt) | 2019-02-12 |
JP2019514927A (ja) | 2019-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6999575B2 (ja) | マイクロrna組成物並びにその作製及び使用方法 | |
Wang et al. | Fetal dermal mesenchymal stem cell‐derived exosomes accelerate cutaneous wound healing by activating notch signaling | |
JP6952761B2 (ja) | 組織修復のための臍帯血由来エキソソームの使用 | |
JP6353073B2 (ja) | 細胞回復のための組成物並びにその作製及び使用方法 | |
JP6900358B2 (ja) | 細胞復元のための無細胞組成物及び同組成物の作成及び使用方法 | |
US10717981B2 (en) | Therapeutic compositions and methods of making and using the same | |
JP5199253B2 (ja) | カテコールアミン受容体の調節 | |
US10772911B2 (en) | Cell free compositions for cellular restoration and methods of making and using same | |
JP6721252B2 (ja) | 皮膚T細胞リンパ腫(CTCL)を処置するためのmiR−155阻害剤 | |
US11286463B2 (en) | Reprogramming of aged adult stem cells | |
US10519441B2 (en) | Use of miRNA-214 inhibitor in inhibiting regulatory cells | |
US20220220561A1 (en) | Methods and clinical protocols and kits pertaining to making and using therapeutic compositions for cellular treatment | |
KR20190005209A (ko) | 고혈당으로 인해 유발되는 섬유성 질환의 치료에 사용하기 위한 miRNA를 함유하는 약제학적 담체 | |
JP6532653B2 (ja) | 造血幹細胞の増殖方法 | |
US9199028B2 (en) | Use of entrained neutrophils to treat metastatic and micrometastatic disease in at risk patients | |
US20230043806A1 (en) | Induction of highly efficacious anti-tumor and immune modulating activity: cell-free off the shelf therapeutic modality | |
Rehman et al. | Impaired Barrier Integrity of the Skeletal Muscle Vascular Endothelium Drives Progression of Cancer Cachexia | |
White | Characterisation of microglia's inflammatory response and investigation of the effect of mesenchymal stem cells-conditioned media | |
CN116173016A (zh) | 5-羟基色氨酸的用途及其与pd-1抗体的组合物及其用途 | |
CN116440162A (zh) | 一种具有哺乳动物心脏系统抗衰作用的生物制品及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210601 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220712 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221209 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230106 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230314 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230614 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230808 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230831 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7343549 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |